Drug Profile
Research programme: menorrhagia therapeutics - Arbor Pharmaceuticals
Alternative Names: Tranexamic acid prodrug; XP 21510Latest Information Update: 26 May 2022
Price :
$50
*
At a glance
- Originator XenoPort
- Class
- Mechanism of Action Plasminogen activator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Menorrhagia
Most Recent Events
- 27 Mar 2012 Suspended - Preclinical for Menorrhagia in USA (PO)
- 31 Jul 2009 XP 21510 is no longer licensed to Xanodyne Pharmaceuticals in USA
- 31 Oct 2008 Preclinical development is ongoing for Menorrhagia in USA